These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37651273)

  • 41. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
    Sperling RA; Jack CR; Black SE; Frosch MP; Greenberg SM; Hyman BT; Scheltens P; Carrillo MC; Thies W; Bednar MM; Black RS; Brashear HR; Grundman M; Siemers ER; Feldman HH; Schindler RJ
    Alzheimers Dement; 2011 Jul; 7(4):367-85. PubMed ID: 21784348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
    Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Re: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2023 Feb; 48(2):168-169. PubMed ID: 36607365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Passive Alzheimer's immunotherapy: A promising or uncertain option?
    Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B
    Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
    Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
    J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
    Cummings J; Osse AML; Cammann D; Powell J; Chen J
    BioDrugs; 2024 Jan; 38(1):5-22. PubMed ID: 37955845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.
    Cummings J
    Drugs; 2023 May; 83(7):569-576. PubMed ID: 37060386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.
    Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Saadatpour Z; Wheeler CA; Natelson Love M; Tanwar M
    Front Radiol; 2023; 3():1305390. PubMed ID: 38249159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Impact of Anti-Amyloid Immunotherapies on Stroke Care.
    Bilodeau PA; Dickson JR; Kozberg MG
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.
    DiFrancesco JC; Longoni M; Piazza F
    Front Neurol; 2015; 6():207. PubMed ID: 26441825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic anti-amyloid β antibodies cause neuronal disturbances.
    Adhikari UK; Khan R; Mikhael M; Balez R; David MA; Mahns D; Hardy J; Tayebi M
    Alzheimers Dement; 2023 Jun; 19(6):2479-2496. PubMed ID: 36515320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab.
    Sveikata L; Charidimou A; Viswanathan A
    Stroke; 2022 Jan; 53(1):298-302. PubMed ID: 34905943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.
    Lacorte E; Ancidoni A; Zaccaria V; Remoli G; Tariciotti L; Bellomo G; Sciancalepore F; Corbo M; Lombardo FL; Bacigalupo I; Canevelli M; Piscopo P; Vanacore N
    J Alzheimers Dis; 2022; 87(1):101-129. PubMed ID: 35275549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three major effects of APOE
    Foley KE; Wilcock DM
    Front Aging Neurosci; 2024; 16():1412006. PubMed ID: 38756535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies.
    Boncoraglio GB; Piazza F; Savoiardo M; Farina L; DiFrancesco JC; Prioni S; Tagliavini F; Parati EA; Giaccone G
    J Alzheimers Dis; 2015; 45(2):363-7. PubMed ID: 25537009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
    Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
    J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.